Oxaliplatin Treatment Alters Systemic Immune Responses

Figure 4

Effects of oxaliplatin on the proportion of M1/M2 phenotypes and pro-/anti-inflammatory cytokines within the spleen. To determine any changes in the proportions of pro-inflammatory and anti-inflammatory macrophages, a set of gating strategies were used. M1 macrophages were gated on CD45⁺ CD11B⁺, Ly6G⁺ Ly6C⁺, CD11C⁺ MHC-II⁺, CD206⁺ CD45⁺ cells. M2 macrophages were gated on: CD45⁺ CD11B⁺, Ly6G⁺ CD45⁺, CD11B⁺ MHC-II⁺, CD206⁺ CD45⁺ cells. To investigate any changes to pro-inflammatory cytokine expression cells were gated on their expression of M1 phenotypes versus IL-6, TNF-α, IL-10 and TGFβ. To determine the expression of anti-inflammatory cytokines from M2 macrophages cells were gated on their phenotype versus IL-10 or TGF-β. No differences in M1 macrophages were observed between the vehicle-treated and oxaliplatin-treated animals (a). No differences were observed in M2 macrophages amongst the vehicle-treated and oxaliplatin-treated animals (a). No changes in M1 or M2 cytokines were observed between the vehicle-treated and oxaliplatin-treated mice (b, c). Vehicle: n=9; oxaliplatin: n=14.

(a)

(b)

(c)